Patent Case Watch

Patent opinions from the Eastern District of Texas and the U.S. Court of Appeals for the Federal Circuit

Fed. Cir.

Astrazeneca AB v. Hanmi USA, Inc., No. 13-1490 (Fed. Cir. Dec. 19, 2013)

Affirmed
Claim Construction Non-Infringement
Court
U.S. Court of Appeals for the Federal Circuit
Case No.
No. 13-1490
Decided
December 19, 2013
Judge
Taranto, J.
Document
Nonprecedential Opinion
Length
10 pages

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Plaintiffs AstraZeneca AB, Aktiebolaget Hassle, AstraZeneca LP, KBI Inc., and KBI -E Inc. (collectively, AstraZeneca) sued Defendants Hanmi USA , Inc., Hanmi Pharmaceutical Co., Ltd., Hanmi Fine Chemical Co., Ltd. , and Hanmi Science Co., Ltd., form erly Hanmi Holdings Co., Ltd. (collectively, Hanmi ). Invoking 35 U.S.C. § 271(e)(2), AstraZeneca alleged that a drug Hanmi proposed to market falls within claims of U.S. Patent Nos. 5,714,504 and 5,877, 192.

Download Opinion (PDF)

Source: govinfo.gov USCOURTS collection · retrieved July 23, 2026 · Report an error